Stephens Consulting’s PTC Therapeutics PTCT Stock Holding History

Stephens Consulting’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20	Closed	-$1.02K	–	1796
2025 Q1	$1.02K	Buy	+20	New	+$998	﹤0.01%	637

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's PTCT Position: Q2 2025 in Review

Stephens Consulting sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 20 shares — an estimated $1.02K sold.

Stephens Consulting first reported a position in PTCT in Q1 2025 and held it in 1 quarter. The position peaked at $1.02K in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

Stephens Consulting reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 20 PTC Therapeutics shares in Q2 2025, an estimated $1.02K.
Stephens Consulting first reported a position in PTC Therapeutics in Q1 2025 and held it in 1 quarter.
Stephens Consulting's PTC Therapeutics position peaked at $1.02K in Q1 2025.
283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.